Michael John Sumner's most recent trade in Inovio Pharmaceuticals Inc was a trade of 46,876 Common Stock Option done . Disclosure was reported to the exchange on May 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2026 | 46,876 | 46,876 | - | - | Common Stock Option | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2026 | 37,684 | 37,684 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2026 | 9,450 | 18,900 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2026 | 9,450 | 44,731 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.23 per share. | 20 May 2026 | 2,693 | 42,038 (0%) | 0% | 1.2 | 3,312 | Common Stock |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 2,385 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 2,385 | 35,961 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 15 May 2026 | 680 | 35,281 (0%) | 0% | 1.3 | 884 | Common Stock |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 4,292 | 34,799 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 4,292 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.74 per share. | 31 Mar 2026 | 1,223 | 33,576 (0%) | 0% | 1.7 | 2,128 | Common Stock |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 36,832 | 36,832 | - | - | Common Stock Option | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 29,608 | 29,608 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 11,550 | 23,100 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 11,550 | 34,410 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 5,010 | 5,009 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2026 | 5,010 | 22,860 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.79 per share. | 26 Feb 2026 | 3,903 | 30,507 (0%) | 0% | 1.8 | 6,986 | Common Stock |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 2,916 | 17,850 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 2,916 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 35,100 | 35,100 | - | - | Common Stock Option | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 28,350 | 28,350 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 2,385 | 2,385 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 2,385 | 15,614 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.95 per share. | 15 May 2025 | 680 | 14,934 (0%) | 0% | 2.0 | 1,326 | Common Stock |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 42,900 | 42,900 | - | - | Common Stock Option | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 34,650 | 34,650 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,010 | 10,019 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 5,010 | 13,229 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael Sumner John | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 5,708 | 5,708 | - | - | Common Stock Option | |
| Inovio Pharma Inc | John Michael Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 4,292 | 4,292 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 2,917 | 8,219 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2024 | 2,917 | 2,916 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,386 | 5,302 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,386 | 4,770 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | John Michael Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 18,750 | 18,750 | - | - | Common Stock Option | |
| Inovio Pharma Inc | John Sumner Michael | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 15,029 | 15,029 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 35,000 | 70,000 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 35,000 | 35,000 (0%) | 0% | - | Common Stock | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 85,878 | 85,878 | - | - | Restricted Stock Unit | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 112,500 | 112,500 | - | - | Common Stock Option | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 160,000 | 160,000 | - | - | Common Stock Options | |
| Inovio Pharma Inc | Michael John Sumner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 105,000 | 105,000 | - | - | Restricted Stock Unit |